Загрузка...
Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
BACKGROUND: Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m(2)). However, recent trial data have shown that these medications have renal...
Сохранить в:
| Опубликовано в: : | Cardiovasc Diabetol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8237469/ https://ncbi.nlm.nih.gov/pubmed/34183018 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01316-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|